Johnson & Johnson (JNJ) Statistics

Johnson & Johnson (JNJ) is a multinational corporation specializing in pharmaceuticals, medical devices, and consumer packaged goods. As of 2021, JNJ stock statistics indicate that the company has a market capitalization of over $400 billion, making it one of the largest healthcare companies in the world. The stock has a price-to-earnings ratio of around 20, reflecting the market's confidence in its performance. In terms of valuation metrics, Johnson & Johnson's price-to-sales ratio stands at approximately 5, indicating that investors are willing to pay a premium for the company's revenue. Additionally, JNJ has an enterprise value-to-EBITDA ratio of around 15, which suggests that it is operating profitably and efficiently.

On the fundamental side, Johnson & Johnson boasts impressive financials. The company has consistently generated strong revenue, with its revenue per share standing at around $27. This demonstrates its ability to generate significant income for its shareholders. Furthermore, JNJ has consistently maintained a high-profit margin, indicating its ability to generate substantial profits from its operations. Additionally, the company has managed its debt effectively, with total debt at a manageable level. This allows Johnson & Johnson to invest in research and development, as well as other growth initiatives. Lastly, JNJ's gross profit remains robust, demonstrating its ability to generate revenue after accounting for the cost of goods sold.